
Product Data Sheet

Product Name: NDB
Cat. No.: GC69541

Chemical Properties

Cas. No. 1660153-08-1

Formula $C_{26}H_{28}Cl_2N_2O_2$ M.Wt 471.42

Solubility DMSO : 100 mg/mL (212.13 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

NDB is a selective **human FXR α (hFXR α)** antagonist that is effective in modulating transcription of FXR α downstream genes. NDB can be used in anti-diabetes research^[1].

NDB induces rearrangements of helix 11 (H11) and helix 12 (H12, AF-2) by forming a homodimer of hFXR α -LBD, totally different from the active conformation in monomer state^[1].

NDB (25 μ M) effectively antagonizes the GW4064-stimulated FXR/RXR interaction and FXR α target gene expression in primary mouse hepatocytes, including the small heterodimer partner (SHP) and bile-salt export pump (BSEP)^[1].

NDB (24 mg/kg; intraperitoneal injection; once a day; for 4 weeks) efficiently decreases the gene expressions of phosphoenolpyruvate carboxykinase (PEPCK), glucose 6-phosphatase (G6-pase), small heterodimer partner, and BSEP in db/db mice^[1].

Animal Model: Male C57BL/6J db/db mice (8 weeks of age)^[1]

Dosage: 24 mg/kg

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Administration: Intraperitoneal injection; once a day; for 4 weeks

Result: Decreased the gene expressions of PEPCCK, G6-pase, small heterodimer partner, and BSEP.

[1]. Xing Xu, et al. Structural Basis for Small Molecule NDB (N-Benzyl-N-(3-(tert-butyl)-4-droxyphenyl)-2,6-dichloro-4-(dimetlamino) Benzamide) as a Selective Antagonist of Farnesoid X Receptor α (FXR α) in Stabilizing the Homodimerization of the Receptor.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA